New Gilead-Sponsored Post-Marketing Trial for Tecartus (ZUMA-2 Cohort 3) in R/R MCL
Here is a brief preview of this blast: On Monday, May 10, a new post-marketing Tecartus Ph2 ZUMA-2 Cohort 3 trial in r/r MCL was observed on CT.gov. Below, Celltelligence provides insights on the study's design and how Gilead could leverage this trial to gain a full FDA approval for Tecartus.